yield10.png
Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024
March 28, 2024 16:01 ET | Yield10 Bioscience, Inc.
WOBURN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 19, 2024 16:05 ET | Cyclacel
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support...
Logo 400x400.jpg
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
March 14, 2024 16:39 ET | CytoSorbents
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024 16:05 ET | Cyclacel
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
ROIC_ NEW logo_blue text transparent background.png
Retail Opportunity Investments Corp. Schedules First Quarter Earnings Release and Conference Call
March 11, 2024 09:00 ET | Retail Opportunity Investments Corp.
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Retail Opportunity Investments Corp. (NASDAQ: ROIC) will issue financial and operational results for the first quarter ended March 31, 2024, after the...
Arbutus Biopharma Logo
Arbutus to Participate in Two Upcoming Investor Conferences
March 08, 2024 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
March 07, 2024 16:01 ET | MacroGenics, Inc.
Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I...
Optinose_logo_RGB.png
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
March 07, 2024 07:00 ET | Optinose, Inc.
PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis Physicians...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
March 06, 2024 07:01 ET | HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
Logo 400x400.jpg
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
March 06, 2024 07:00 ET | CytoSorbents
PRINCETON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...